Carbatrol
Company: Elan
Approval Status: Approved September 1997
Treatment for: anticonvulsant and trigeminal neuralgia
Areas: Neurology
General Information
Other Useful Resources
Carbatrol by Elan Corp. has been approved as a treatment for epileptic seizures and trigeminal neuralgia. Carbatrol is recommended for use twice daily as an extended release drug.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
